{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:51:03Z","timestamp":1761659463305,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ajg.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T08:23:07Z","timestamp":1675066987000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of liver fibrosis after interferon-based anti-hepatitis C virus therapy failure in 3,049 chronic hepatitis C patients without cirrhosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-1141","authenticated-orcid":false,"given":"Heba","family":"Omar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9857-8972","authenticated-orcid":false,"given":"Imam","family":"Waked","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafaa","family":"Elakel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabab","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Abdel-Razik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham","family":"Elmakhzangy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser Omar","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramy","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-6172","authenticated-orcid":false,"given":"Arwa","family":"Elshafaey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina H.","family":"Ziada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohier Ahmed","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5648-7733","authenticated-orcid":false,"given":"Hany M.","family":"Dabbous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal","family":"Esmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajg.2023.01.002_b0005","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/hep.510290528","article-title":"Modeling the hepatitis C virus epidemic in France","volume":"29","author":"Deuffic","year":"1999","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.ajg.2023.01.002_b0010","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajg.2023.01.002_b0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jhep.2010.01.033","article-title":"Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study","volume":"53","author":"Omland","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2023.01.002_b0020","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. http:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2016\/en\/. Last accessed July 20, 2018."},{"key":"10.1016\/j.ajg.2023.01.002_b0025","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org\/full-report-view. Last accessed 4\/24\/2018."},{"key":"10.1016\/j.ajg.2023.01.002_b0030","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J. Hepatol. 66, 153\u2013194, doi:10.1016\/j.jhep.2016.09.001 (2017).","DOI":"10.1016\/j.jhep.2016.09.001"},{"issue":"21","key":"10.1016\/j.ajg.2023.01.002_b0035","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajg.2023.01.002_b0040","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial."},{"issue":"3","key":"10.1016\/j.ajg.2023.01.002_b0045","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","article-title":"Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"135","author":"Maylin","year":"2008","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.ajg.2023.01.002_b0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ajg.2023.01.002_b0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1665-2681(19)30840-3","article-title":"Long term changes in liver histology following treatment of chronic hepatitis C virus","volume":"13","author":"Shiffman","year":"2014","journal-title":"Ann Hepatol"},{"issue":"16","key":"10.1016\/j.ajg.2023.01.002_b0060","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajg.2023.01.002_b0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/gut.2003.021691","article-title":"Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study","volume":"53","author":"Ryder","year":"2004","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ajg.2023.01.002_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2893.2009.01262.x","article-title":"Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection","volume":"18","author":"Williams","year":"2011","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.ajg.2023.01.002_b0075","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamainternmed.2014.6502","article-title":"Liver fibrosis progression in hepatitis C virus infection after seroconversion","volume":"175","author":"Butt","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.ajg.2023.01.002_b0080","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis patients with HIV\/HCV co-infection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ajg.2023.01.002_b0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ajg.2023.01.002_b0090","doi-asserted-by":"crossref","unstructured":"Sheth SG, Flamm SL, Gordon FD, Chopra S. AST\/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. 1998.","DOI":"10.1111\/j.1572-0241.1998.044_c.x"},{"issue":"2","key":"10.1016\/j.ajg.2023.01.002_b0095","first-page":"77","article-title":"Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level","volume":"60","author":"Ohta","year":"2006","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.ajg.2023.01.002_b0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ajg.2023.01.002_b0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MCG.0000000000000753","article-title":"Does incorporating change in apri or fib-4 indices over time improve the accuracy of a single index for identifying liver fibrosis in persons with chronic hepatitis c virus infection?","volume":"52","author":"Gounder","year":"2018","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.ajg.2023.01.002_b0110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2893.2012.01635.x","article-title":"Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C","volume":"20","author":"Tamaki","year":"2013","journal-title":"J Viral Hepat"},{"issue":"9055","key":"10.1016\/j.ajg.2023.01.002_b0115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ajg.2023.01.002_b0120","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cgh.2016.01.009","article-title":"Chronic Hepatitis Cohort Study Investigators.Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection","volume":"14","author":"Lu","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ajg.2023.01.002_b0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation","volume":"65","author":"Martin","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2023.01.002_b0130","unstructured":"American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C: When and in Whom to Initiate HCV Therapy. https:\/\/www.hcvguidelines.org\/evaluate\/when-whom. Accessed August 02, 2019."},{"key":"10.1016\/j.ajg.2023.01.002_b0135","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"issue":"1","key":"10.1016\/j.ajg.2023.01.002_b0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12954-019-0303-9","article-title":"Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries","volume":"16","author":"Maticic","year":"2019","journal-title":"Harm Reduct J"},{"issue":"2","key":"10.1016\/j.ajg.2023.01.002_b0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2468-1253(17)30284-4","article-title":"Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe","volume":"3","author":"Marshall","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2023.01.002_b0150","unstructured":"National Viral Hepatitis Roundtable (NVHR), Center for Health Law and Policy Innovation of Harvard Law School (CHLPI). Hepatitis C: State of Medicaid Access Report. https:\/\/stateofhepc.org. Published 2019. Accessed August 02, 2019."},{"key":"10.1016\/j.ajg.2023.01.002_b0155","unstructured":"Scrase DR, Thornton K, Carvour ML, et al. Care Redesign: A Collaborative Model to Expand Medicaid Treatment Coverage for Chronic Hepatitis C Virus. https:\/\/catalyst.nejm.org\/collaborative-chronic-hcv-coverage\/. Published 2019. Accessed August 02, 2019."}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197923000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197923000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:46:20Z","timestamp":1761659180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687197923000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1687197923000035"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2023.01.002","relation":{},"ISSN":["1687-1979"],"issn-type":[{"type":"print","value":"1687-1979"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of liver fibrosis after interferon-based anti-hepatitis C virus therapy failure in 3,049 chronic hepatitis C patients without cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Arab Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajg.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}